Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic LeukemiaKathryn G. Roberts, Timothy P. Hughes, Gang Wu et al.|New England Journal of Medicine|2014Cited by 1.4k
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, Susan Branford et al.|Blood|2013Cited by 705
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk diseaseSusan Branford, Timothy P. Hughes, Paul Wang et al.|Blood|2018Cited by 208
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Michael Osborn et al.|Blood|2014Cited by 102
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsTimothy P. Hughes, David M. Ross, Ilaria S. Pagani et al.|Leukemia|2018Cited by 78